{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:34:03Z","timestamp":1793691243500,"version":"4.5.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Institutional Program for Scientific Initiation Scholarships"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.virusres.2020.198251","type":"journal-article","created":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T11:07:10Z","timestamp":1606561630000},"page":"198251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Natural prevalence of NS3 gene resistance-associated substitutions (RASs) in patients with chronic hepatitis C from the state of Par\u00e1\/Brazil"],"prefix":"10.1016","volume":"292","author":[{"given":"Desir\u00e9e Lopes","family":"da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heloisa Marceliano","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9789-4180","authenticated-orcid":false,"given":"Pedro Eduardo Bonfim","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.virusres.2020.198251_bib0005","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/liv.14502","article-title":"Phase 3, multicenter open-label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naive, HCV GT1b-infected patients, with non-severe fibrosis","volume":"40","author":"Abergel","year":"2020","journal-title":"Liver Int."},{"issue":"3","key":"10.1016\/j.virusres.2020.198251_bib0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.clinre.2019.07.015","article-title":"Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil","volume":"44","author":"Aguiar","year":"2019","journal-title":"Clin. Res. Hepatol. Gatroenterol."},{"key":"10.1016\/j.virusres.2020.198251_bib0015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1478-3231.2010.02411.x","article-title":"New direct-acting antivirals combination of the treatment of chronic hepatitis C","volume":"1","author":"Asselah","year":"2011","journal-title":"Liver Int."},{"key":"10.1016\/j.virusres.2020.198251_bib0020","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1478-3231.2011.02699.x","article-title":"Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow","volume":"1","author":"Asselah","year":"2012","journal-title":"Liver Int."},{"issue":"4","key":"10.1016\/j.virusres.2020.198251_bib0025","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jhep.2017.11.037","article-title":"Eliminating hepatitis C within low income countries \u2013 the need to cure genotypes 4,5,6","volume":"68","author":"Asselah","year":"2017","journal-title":"J. Hepatol."},{"issue":"S1","key":"10.1016\/j.virusres.2020.198251_bib0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.13673","article-title":"Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int."},{"issue":"11","key":"10.1016\/j.virusres.2020.198251_bib0035","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","article-title":"Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes","volume":"218","author":"Borgia","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virusres.2020.198251_bib0040","doi-asserted-by":"crossref","first-page":"20310","DOI":"10.1038\/srep20310","article-title":"Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data","volume":"6","author":"Cheng","year":"2016","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.virusres.2020.198251_bib0045","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.clinre.2019.02.009","article-title":"Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1","volume":"43","author":"Costa","year":"2019","journal-title":"Clin. Res. Hepatol. Gatroenterol."},{"issue":"5","key":"10.1016\/j.virusres.2020.198251_bib0050","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/cld.631","article-title":"Resistance testing: interpretation and incorporation into HCV treatment algorithms","volume":"9","author":"Feld","year":"2017","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.virusres.2020.198251_bib0055","series-title":"Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection","first-page":"4","author":"Geneva: World Health Organization","year":"2018"},{"issue":"1","key":"10.1016\/j.virusres.2020.198251_bib0060","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","article-title":"Hepatitis C virus resistance to protease inhibitors","volume":"55","author":"Halfon","year":"2011","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.virusres.2020.198251_bib0065","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz076","article-title":"Identification of 19 novel hepatitis C virus subtypes \u2013 further expanding HCV classification","volume":"6","author":"Hedskog","year":"2019","journal-title":"Open Forum Infect. Dis."},{"issue":"40","key":"10.1016\/j.virusres.2020.198251_bib0070","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.3748\/wjg.v22.i40.8910","article-title":"Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database","volume":"22","author":"Kliemann","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.virusres.2020.198251_bib0075","first-page":"3","article-title":"Overview of direct-acting antiviral drugs and drug resistance of hepatitis C virus","volume":"1911","author":"Li","year":"2019"},{"issue":"10","key":"10.1016\/j.virusres.2020.198251_bib0080","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1007\/s00705-018-3920-9","article-title":"Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3\/NS4A protease inhibitors in S\u00e3o Paulo state","volume":"163","author":"Moreira","year":"2018","journal-title":"Arch. Virol."},{"issue":"3","key":"10.1016\/j.virusres.2020.198251_bib0085","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3851\/IMP2873","article-title":"Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection","volume":"20","author":"Neto-Lisboa","year":"2015","journal-title":"Antivirus Ther."},{"issue":"1","key":"10.1016\/j.virusres.2020.198251_bib0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227082","article-title":"HCV genotype profile in Brazil of mono-infected and HIV co-infected individuals: a survey representative of an entire country","volume":"15","author":"Nutini","year":"2020","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.virusres.2020.198251_bib0095","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment Failure and resistance with direct-acting antiviral drugs against hepatitis C virus","volume":"53","author":"Pawlotsky","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.virusres.2020.198251_bib0100","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virusres.2020.198251_bib0105","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00705-010-0642-z","article-title":"Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy na\u00efve patients","volume":"155","author":"Peres-da-Silva","year":"2010","journal-title":"Arch. Virol."},{"issue":"1","key":"10.1016\/j.virusres.2020.198251_bib0110","first-page":"57","article-title":"Resistance-associated variants to hepatitis C virus protease inhibitors in na\u00efve DAA patients in Brazil","volume":"16","author":"Pess\u00f4a","year":"2014","journal-title":"Rev. Panam Infectol."},{"issue":"2","key":"10.1016\/j.virusres.2020.198251_bib0115","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virusres.2020.198251_bib0120","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.01.003","article-title":"Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region","volume":"116","author":"Sarrazin","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.virusres.2020.198251_bib0125","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.antiviral.2014.02.011","article-title":"Antiviral therapy of hepatitis C in 2014: do we need resistance testing?","volume":"105","author":"Schneider","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.virusres.2020.198251_bib0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018","volume":"37","author":"Sorbo","year":"2018","journal-title":"Drug Resist. Update"},{"issue":"7","key":"10.1016\/j.virusres.2020.198251_bib0135","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/jac\/dkv081","article-title":"Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: implication for simeprevir usage","volume":"70","author":"Vidal","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"issue":"7","key":"10.1016\/j.virusres.2020.198251_bib0140","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S2468-1253(17)30071-7","article-title":"Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial","volume":"2","author":"Welzel","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.virusres.2020.198251_bib0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1590\/S0074-02762013000100002","article-title":"Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors","volume":"108","author":"Zeminian","year":"2013","journal-title":"Mem. Inst. Oswaldo Cruz"}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170220311588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170220311588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:11:15Z","timestamp":1759155075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170220311588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":29,"alternative-id":["S0168170220311588"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2020.198251","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural prevalence of NS3 gene resistance-associated substitutions (RASs) in patients with chronic hepatitis C from the state of Par\u00e1\/Brazil","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2020.198251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"198251"}}